Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040090 · ClinicalTrials.gov registry record · Phase 2
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
A Phase 2 study of Rabies, sponsored by Kamada.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 1
- Study location
NCT02040090 is a Phase 2 study of Rabies that has completed, run by Kamada. The registered enrollment target is 118 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02040090, a Phase 2 study of Rabies, has completed, sponsored by Kamada.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as compared to the HRIG comparator product, also given in conjunction with the active rabies vaccine.
Conditions Studied
Interventions
- DRUG Active rabies vaccine (US-FDA approved)
Study Locations (1)
Minnesota
- Prism Research Inc - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02040090
The ClinicalTrials.gov registry entry for NCT02040090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kamada, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rabies appearing as the primary indexed condition, and to 1 intervention - of which Active rabies vaccine (US-FDA approved) is the first listed.
NCT02040090 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02040090 about?
NCT02040090 is a clinical study titled "Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects". The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as...
What is the current status of trial NCT02040090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2013-04. Estimated completion is 2014-08.
What conditions does trial NCT02040090 study?
This clinical trial studies the following conditions: Rabies.
What interventions are being tested in trial NCT02040090?
The interventions under investigation include: Active rabies vaccine (US-FDA approved) (DRUG).
Who is sponsoring clinical trial NCT02040090?
This trial is sponsored by Kamada, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02040090 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rabies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.